Theravance Biopharma股价暴跌26%，因试验失败后公司探讨出售

关键事实

1The Phase 3 CYPRESS study evaluating ampreloxetine failed to meet its primary endpoint in patients with symptomatic neurogenic orthostatic hypotension (nOH).

2The board is accelerating a strategic review and announced an organizational restructuring to reduce the cost base by approximately 60% (around $70 million).

3The company expects a cash balance of approximately $400 million by the end of Q1 2026, shifting focus to its growing COPD product, YUPELRI.

Theravance Biopharma (TBPH) 股价在早盘交易中暴跌26%，此前有消息称，其用于安普罗西汀的3期CYPRESS研究未能达到主要终点。该试验专门评估了该药物在多系统萎缩症 (MSA) 患者中的疗效，多系统萎缩症是一种罕见的神经系统疾病。为应对这一临床挫折，该公司已聘请拉扎德 (Lazard) 探讨出售业务的可能性，作为加速战略审查的一部分。与此同时，Theravance 正在实施一项重大重组计划，旨在将其成本基础削减60%，即每年约7000万美元。该公司现在将把重点转向其商业产品YUPELRI，以推动现金流，同时预计到2026年第一季度末保持4亿美元的现金余额。这一战略转变凸显了该公司在失去关键增长催化剂后，迫切需要保留资本并最大化其剩余资产的价值。

免费注册以访问此内容

创建免费账户

版本历史

版本 125 days ago

变更内容: Updated to include the 26% share price plunge, the engagement of Lazard to explore a potential sale, and the specification that the trial targeted multiple system atrophy (MSA).

来源: